FRANCISCO JAVIER
CAPOTE HUELVA
Researcher in the period 2010-2024
KU Leuven
Lovaina, BélgicaPublications in collaboration with researchers from KU Leuven (1)
2018
-
Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study
The Lancet Oncology, Vol. 19, Núm. 11, pp. 1449-1458